CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes

Drug Metabolism and Disposition

Volumn 35, Issue 1, 2007, Pages 128-138

  Davies, Benjamin J ^a,b   Coller, Janet K ^a   Somogyi, Andrew A ^a   Milne, Robert W ^c   Sallustio, Benedetta C ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; HYDROXYPERHEXILINE; MONOCLONAL ANTIBODY; PERHEXILINE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; DRUG BINDING; DRUG CLEARANCE; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CLEARANCE; LIVER MICROSOME; PRIORITY JOURNAL; STEREOCHEMISTRY;

ANTIBODIES, MONOCLONAL; CARDIOVASCULAR AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; OXIDATION-REDUCTION; PERHEXILINE; RECOMBINANT PROTEINS; STEREOISOMERISM;

EID: 33845923933     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012252     Document Type: Article

References (42)

1. Baldwin S, Bloomer J, Smith G, Ayrton A, Clarke S, and Chenery R (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
2. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
3. Born SL, Caudill D, Fliter KL, and Purdon MP (2002) Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation. Drug Metab Dispos 30:483-487.
4. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, Hartley LH, Smith TW, and Antman E (1990) Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 81: 1260-1270.
5. Cooper JDH, Turnell DC, Pilcher J, and Lockhart D (1985) Therapeutic monitoring of the anti-anginal drug perhexiline maleate. Ann Clin Biochem 22:614-617.
6. Cooper RG, Evans DAP, and Whibley EJ (1984) Polymorphic hydroxylation of perhexiline maleate in man. J Med Genetics 21:27-33.
7. Daly AK (2004) Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 4:1733-1744.
8. Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, and Sallustio BC (2006a) The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. Br J Clin Pharmacol 61:321-325.
9. Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, and Sallustio BC (2006b) Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. J Chromatogr B 843:302-309.
10. Davies BJ, Herbert MK, Culbert JA, Pyke SM, Coller JK, Somogyi AA, Milne RW, and Sallustio BC (2006c) Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. J Chromatogr B 832:114-120.
11. Davies BJL, Sallustio BC, Somogyi AA, Coller JK, and Milne RW (2005) In vitro enantioselective human metabolism of perhexiline. Proc Aust Soc Clin Exp Pharmacol Toxicol 11:162.
12. Ekins S and Wrighton SA (1999) The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31:719-754.
13. Gillam EM, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PE, Hooper WD, and Guengerich FP (1995) Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 317:374-384.
14. Gould BJ, Amoah AGB, and Parke DV (1986) Stereoselective pharmacokinetics of perhexiline. Xenobiotica 16:491-502.
15. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
16. Hutchinson MR, Menelaou A, Foster DJR, Coller JK, and Somogyi AA (2004) CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 57:287-297.
17. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
18. Inglis SC, Herbert MK, Davies BJ, Coller JK, James HM, Horowitz JD, Morris RG, Milne RW, Somogyi AA, and Sallustio BC (2006) Effect of CYP2D6 metaboliser status on the disposition of the (+)- and (-)-enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenet Genomics, in press.
19. James HM, Coller JK, Gillis D, Bahnisch J, Sallustio BC, and Somogyi AA (2004) A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. Int J Clin Pharmacol Ther 42:719-723.
20. Lewis DF, Modi S, and Dickins M (2002) Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev 34:69-82.
21. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
22. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
23. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, and Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202.
24. McLure JA, Miners JO, and Birkett DJ (2000) Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
25. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, and Sherlock S (1984) Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25:1057-1064.
26. Newton D, Wang R, and Lu A (1995) Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
27. Notley LM, de Wolf CJ, Wunsch RM, Lancaster RG, and Gillam EM (2002) Bioactivation of tamoxifen by recombinant human cytochrome P450 enzymes. Chem Res Toxicol 15:614-622.
28. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 234:2374-2385.
29. Rae JM, Soukhova NV, Flockhart DA, and Desta Z (2002) Triethylenephosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphoramide metabolism. Drug Metab Dispos 30:525-530.
30. Raimundo S, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M, Schwab M, and Zanger UM (2004) A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76:128-138.
31. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
32. Rodriguez-Antona C, Jover R, Gomez-Lechon MJ, and Castell JV (2000) Quantitative RT-PCR measurement of human cytochrome P-450s: application to drug induction studies. Arch Biochem Biophys 376:109-116.
33. Sallustio BC, Westley IC, and Morris RG (2002) Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady state dose. Br J Clin Pharmacol 54:107-114.
34. Shah RR, Oates NS, Idle JR, Smith RL, and Lockhart JDF (1982) Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 284:295-299.
35. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
36. Sørensen LB, Sørensen RN, Miners JO, Somogyi AA, Grgurinovich N, and Birkett DJ (2003) Polymorphic hydroxylation of perhexiline in vitro. Br J Clin Pharmacol 55:635-638.
37. Stresser DM and Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525.
38. Tang W and Stearns RA (2001) Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2:185-198.
39. Tracy TS and Hummel MA (2004) Modeling kinetic data from in vitro drug metabolism enzyme experiments. Drug Metab Rev 36:231-242.
40. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br J Clin Pharmacol 52:107-117.
41. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M, and Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585.
42. Zanger UM, Vilbois F, Hardwick JP, and Meyer UA (1988) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27:5447-5454.